featured
2024 Top Story in Metastatic Breast Cancer: First-Line Inavolisib, Palbociclib, and Fulvestrant in Patients With PIK3CA-Mutated, HR-Positive Metastatic Breast Cancer
Written by
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Turner NC, Slamon DJ, Ro J, et al. Overall Survival With Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926–1936.
- Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J. 2016;375(20):1925–1936.
- Turner NC, Im SA, Saura C, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. N Engl J Med. 2024;391(17):1584–1596.
- André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–1940.
-
Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058–2070. https://www.nejm.org/doi/10.1056/NEJMoa2214131
Disclosure statements are available on the authors' profiles: